Intas

Aurobindo Pharma and Intas are in the race to buy UK-based Mallinckrodt's generic drugs business in the US valued at USD 2 billion, this will be the biggest ever overseas acquisition for any Indian drug maker.

Has the Indian pharmaceutical sector become a soft target?

The last couple of years have been very unsettling for the sector. It has declined by 25 percent from five-year (2012-16) Compound Annual Growth Rate of 12 percent.

Aurobindo's topline can swell by $350 m with Teva buy: PL

Indian pharmaceutical companies Aurobindo and Intas are among the final contenders for Teva‘s generic drug business in UK. The strategy will help the companies expand their European business.